Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

NCT06302621 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Unresectable Solid Tumor
Metastatic Solid Tumor
Cholangiocarcinoma

Interventions

DRUG: Afatinib
DRUG: Pemigatinib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]